Organon & Co. (0A9W)
London Exchange · UK · prices in USD · close of 21 Oct 2026
Key indicators
| Last close | USD 13.77 |
|---|---|
| 52-week range | 5.69 – 13.84 |
| Return, 1 month / 3 months | +0.6% / +1.8% |
| Return, 1 year / 3 years | +50.6% / +3.2% |
| Trend | Uptrend |
| RSI (14) | 55 |
| Volatility (1 year) | 62.1% |
| Worst drawdown (1 year) | -41.9% |
| Average daily value traded | 0.03M USD |
| Dividend yield | 0.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Organon is a pharmaceutical company focused on women's health, offering contraceptives, fertility treatments and related therapies, alongside a portfolio of established medicines and biosimilar products. Its customers are healthcare providers, hospitals and patients, served through prescription channels in markets around the world. The company is based in Jersey City, New Jersey, in the United States, and it operates as an independent business following its separation from a larger drugmaker.
The shares are listed on the London Exchange in UK under the code 0A9W, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Organon & Co. (0A9W) trades on the London Exchange in UK. It last closed at USD 13.77 on 21 October 2026.
Its price-based Market X-Ray is 57 out of 100 (a fair price profile), ranking 1,573 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 50.6% and over the last three months it rose 1.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 92 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 21.1% | ||
| From 52-week high | -0.3% | ||
| Momentum | 77 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 1.8% | ||
| 6-month return | 25.8% | ||
| 12-month return, skipping the last month | 49.7% | ||
| Stability (higher is calmer) | 23 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 62.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -41.9% | ||
| Liquidity | 21 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.03M USD | ||
| Zero-volume days | 6.7% | ||
| Income | 63 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 0.6% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +0.6% |
| 3 months | +1.8% |
| 6 months | +25.8% |
| 1 year | +50.6% |
| 3 years | +3.2% |
| 5 years | −54.3% |
Signals
| 50-day / 200-day average | 13.73 / 11.37 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.04 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Aug 2026 | USD 0.0200 |
| 11 May 2026 | USD 0.0200 |
| 23 Feb 2026 | USD 0.0200 |
| 20 Nov 2025 | USD 0.0200 |
| 15 Aug 2025 | USD 0.0200 |
| 12 May 2025 | USD 0.0200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.